Healthy volunteers help test how a new drug is absorbed

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Part A only: all healthy study participants except for those participants who are eligible for Part B of the study * For participants of Japanese origin (Part B): study participant is of Japanese descent as evidenced by appearance and verbal confirmation of familial heritage (a participant has all 4 Japanese grandparents born in Japan). For participants of Chinese origin (Part B): study participant is of Chinese descent as evidenced by appearance and verbal confirmation of familial heritage (a participant has all 4 Chinese grandparents born in China). * Body weight within 45 to 100 kg (female) and 50 to 100 kg (male) and body mass index (BMI) within the range 18 to 30 kg/m\^2 (inclusive at screening) * Healthy male and female study participants Exclusion Criteria: * Participant has any medical or psychiatric condition that, in the opinion of the Investigator, could jeopardize or would compromise the study participant's ability to participate in this study * Participant has a history or presence of/significant history of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention; or interfering with the interpretation of data * Participant has had lymphoma, leukemia, or any malignancy within the past 5 years, except for basal cell carcinomas that have been resected, squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years * Participant has had breast cancer within the past 10 years * Participant has a history of alcohol or drug abuse within the last 1 year from Screening, as defined according to the Diagnostic and Statistical Manual of Mental Disorders * Participant has a known hypersensitivity to any components of the study medication or comparative drugs as stated in this protocol * Participant has a consumption of more than 600 mg of caffeine/day at screening and throughout the study * Participant has consumed any grapefruit, grapefruit juice, grapefruit-containing products, or star fruit within 14 days prior to administration of study medication or is not willing to refrain from consuming these products for the duration of the study * Participant has previously participated in this study or participant has previously been assigned to treatment in a study of the medication under investigation in this study * Participant has participated in another study of a study medication (and/or an investigational device) within the previous 30 days or 5 half-lives, whichever is greatest, or is currently participating in another study of an study medication (and/or an investigational device) * Presence of hepatitis B surface antigen (HBsAg) at screening or within 3 months prior to dosing * Positive hepatitis C antibody test (HCVAb) result at screening or within 3 months prior to starting study intervention * Positive hepatitis C ribonucleic acid (RNA) test result at screening or within 3 months prior to first dose of study medication * Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones) * For women of childbearing potential, study participant is pregnant, planning on becoming pregnant during the study, or is breastfeeding * Participants who may have a history of confirmed gastric ulceration